Noreen Scherer
Chief Tech/Sci/R&D Officer bij LARIMAR THERAPEUTICS, INC.
Profiel
Noreen Scherer is currently the Vice President-Clinical Operations at Larimar Therapeutics, Inc. and Alcobra, Inc. She previously held the same position at Chondrial Therapeutics, Inc. Ms. Scherer completed her undergraduate degree at LaSalle University.
Actieve functies van Noreen Scherer
| Bedrijven | Functie | Begin |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-05-2018 |
| Alcobra, Inc. | Chief Operating Officer | - |
Eerdere bekende functies van Noreen Scherer
| Bedrijven | Functie | Einde |
|---|---|---|
Chondrial Therapeutics, Inc.
 Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Noreen Scherer
| LaSalle University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LARIMAR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Chondrial Therapeutics, Inc.
Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Alcobra, Inc. |
